Skip to content

Valsartan/Amlodipine/Hydrochlorothiazide

    DEA Class; Rx

    Common Brand Names; Exforge HCT

    • ARB/CCB/Diuretic Combos

    Combination thiazide diuretic and angiotensin II antagonist
    Used for hypertension
    Hyperuricemia compared to diuretic monotherapy; additive efficacy; less potassium loss

    Indicated for the treatment of hypertension.

     

    Hypersensitivity to valsartan, amlodipine, sulfonamide drugs, or other ingredients

    Pregnancy (2nd and 3rd trimesters): Significant risk of fetal/neonatal morbidity and mortality

    Anuria

    Coadministration with aliskiren in patients with diabetes

    Amlodipine

    • Edema (1.8-10.8%)
    • Headache (7.3%)
    • Fatigue (4.5%)
    • Palpitation (0.7-4.5%)
    • Dizziness (1.1-3.4%)
    • Flushing (0.7-2.6%)
    • Nausea (2.9%)
    • Abdominal pain (1.6%)
    • Somnolence (1.4%)

    Valsartan

    • Hyperkalemia (4-10%)
    • Dizziness (2-8%)
    • Hypotension (1-7%)
    • Fatigue (3%)

    Hydrochlorothiazide

    • Anorexia
    • Epigastric distress
    • Hypokalemia
    • Hypotension
    • Phototoxicity

    Avoid with severe hepatic impairment or renal impairment (ie, CrCl <30 mL/min)

    Excessive hypotension may occur (rare); caution if volume/salt depleted, initiate cautiously in patients with heart failure, recent MI, or those undergoing surgery or dialysis

    Worsening angina and acute MI may occur after starting or increasing amlodipine dose, particularly with severe obstructive CAD

    Patients whose renal function may depend in part on the activity of the renin angiotensin system (eg, patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion); correct volume depletion prior to initiation

    Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy; closely monitor blood pressure; monitor renal function and potassium in susceptible patients

    Acute transient myopia and acute angle-closure glaucoma has been reported, particularly with history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide)

    Hydrochlorothiazide may exacerbate systemic lupus erythematosus

    Instruct patients to protect skin from sun and undergo regular skin cancer screening

    Hydrochlorothiazide may alter glucose tolerance and raise cholesterol and triglycerides

    Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricemia and precipitate gout in susceptible patients.

    Hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium; monitor calcium levels in patients with hypercalcemia receiving therapy

    Angiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death

    There is limited information regarding presence of drug in human milk, effects on breastfed infant, or on milk production

    Adults

    10 mg/day PO amlodipine, 320 mg/day PO valsartan, and 25 mg/day hydrochlorothiazide, HCTZ.

    Geriatric

    10 mg/day PO amlodipine, 320 mg/day PO valsartan, and 25 mg/day hydrochlorothiazide, HCTZ.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Valsartan/amlodipine/hydrochlorothiazide

    tablet

    • 5mg/160mg/12.5mg
    • 5mg/160mg/25mg
    • 10mg/160mg/12.5mg
    • 10mg/160mg/25mg
    • 10mg/320mg/25mg